Photo of Talha Badar from mayoclinic.org
Jun 15, 2024, 07:20
Talha Badar: Optimization of venetoclax based therapy
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared on X:
“Wei: Optimization of venetoclax based therapy.
1) use hydrea or flat dose cytarabine to bring WBC below 25k before initiation of Venetoclax.
2) BM biopsy at D21.
3) G-CSF to reduce neutropenic nadir if D21 BM shows blast clearance.
4) MRD clearance may take upto 8 cycles, so continue Ven based regimen if patient is having response.
5) triplet therapy with FLT3i, menin inhibitors etc can reduce risk of Ven resistance.”
Source: Talha Badar/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 7, 2024, 19:46
Nov 7, 2024, 19:43
Nov 7, 2024, 19:36
Nov 7, 2024, 19:32
Nov 7, 2024, 19:28
Nov 7, 2024, 19:24
Nov 7, 2024, 19:11
Nov 7, 2024, 18:06